Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.2 (
alanine aminotransferase
)
26,722
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The influence of hemosorption in multimodality therapy of 71 patients with chronic liver diseases was studied. Together with clinical improvement of the health status hemosorption was followed by a decrease in the concentration of bilirubin, cholesterol and gamma-globulins,
ALT
activity, the level of the thymol test, IgA, IgG and CIC. The content of T-lymphocytes and their subpopulation changed very little. Hemosorption efficacy was more marked in
chronic active hepatitis
and at initial stages of biliary cirrhosis than at the dystrophic stage of biliary cirrhosis. The use of hemosorption in multimodality therapy of patients with chronic liver diseases contributed to faster clinical improvement, return of biochemical and immunological indices to normal.
...
PMID:[Use of hemosorption in the treatment of patients with chronic liver diseases]. 357 64
Eleven patients of Chinese origin experienced spontaneous reactivation of
chronic active hepatitis
B. Eight HBsAg-positive patients were followed for an average of 15 months prior to, while three others presented during reactivation. Fatigue, hepatomegaly and jaundice were frequent findings. Elevation of both serum
ALT
(average = 1,212 units per liter) and hepatitis B virus DNA levels were noted in all patients, and reactivation lasted an average of 4.4 months. During resolution, clinical symptoms abated, serum
ALT
levels reverted toward normal, and in nine patients, the hepatitis B virus DNA values became undetectable. All patients lacked evidence for acute hepatitis A, Epstein-Barr Virus, cytomegalovirus or hepatitis delta virus infection. Histologic findings of liver tissue from eight patients showed piecemeal necrosis and fibrosis. Within the parenchyma, varying degrees of hepatocytolysis with cuffing, perivenular necrosis and acidophilic bodies were noted. Ground-glass cells and regenerative changes also were observed. Cirrhosis was not present in any of the liver biopsies. These findings suggest that spontaneous reactivation of hepatitis B occurs in heterosexual patients with
chronic active hepatitis
B and contributes to chronic inflammation and to the progression of their liver disease.
...
PMID:Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. 361 49
An early detection of the progress to chronic stages of the acute diseases has particular pathogenic and therapeutic implications in hepatology. A complex clinical, biologic and morphologic study has been carried out in 86 patients with persistent acute hepatitis, recently released after 4-8 weeks of hospitalization for acute viral hepatitis, who were submitted to sequential investigations and follow up for a mean period of 16 months (range 2-24 months). All the patients have shown signs of activity of the liver injury, more than three months after the viral hepatitis onset (GOT/
GPT
134 +/- 41 KU/219 +/- 59 KU, gammaglobulins 24.2 +/- 2.4%) and a characteristic immune pattern. In some cases, the morphologic investigations (endo-histologic and infrastructural) have revealed elements of acute and
chronic active hepatitis
. In 70% of the case the disease had a favourable course, while 30% of them showed a tendency to chronicization and even to cirrhosis, within a period of two years.
...
PMID:Persistent acute hepatitis, an evolutive modality of the acute viral hepatitis, with high cirrhogenic potential. 361 42
A study was carried out to confirm the pathogenetic role of ethanol in the development of
chronic active hepatitis
(
CAH
) and to assess if previous or current superimposed hepatitis B virus (HBV) infection could be relevant to the course of alcoholic liver disease (ALD). We examined clinical and laboratory reports of 57 alcoholics with biopsy-proven
CAH
. Serum and/or tissue HBV markers and the presence or absence of cirrhosis were investigated. Alcohol was the only aetiological factor present in a small group of
CAH
, with or without histological findings suggestive of alcoholic damage. Age, sex and survival were similar among the subgroups of
CAH
with and without previous or current HBV infection and among the subgroups of
CAH
with and without associated histological alcoholic features. Among the laboratory data, the AST/
ALT
ratio was higher in
CAH
without previous or current HBV infection. The mean age was comparable in
CAH
patients with and without cirrhosis, whereas the cumulative 5-year survival was worse in
CAH
with cirrhosis (87% vs. 49%). These data suggest a difference in alcohol susceptibility in our subjects.
...
PMID:Features of chronic hepatitis in alcoholics. A survey in Milan. 369 15
Corticosteroids, azathioprine and antiviral agents have a questionable effect on
CAH
B. Chloroquine, a lysosomotropic agent, was used to treat 7 patients with histologically confirmed
CAH
B. All were HBeAb positive. A working hypothesis considering cellular death in
CAH
B as the result of lysosomal enzyme liberation by activated Kupffer cells was the basis for treatment. In this model T lymphocytes have only an immunoregulatory role. Clinical and laboratory follow-up was done for 6-16 months (median 12 months). Serum chloroquine levels were recorded by a fluorimetric method. 150-450 mg of chloroquine base were administered according to bio-chemical disease activity. In all patients AST and
ALT
values returned to normal and there was a fall in serum delta GT and improvement of prothrombin time. an increase of globulins was noted. Inadvertent drug withdrawal resulted in aminotransferase increase in 3 patients with prompt restoration of normal values on readministration. One patient refused to continue the drug and died after two months. Variceal bleeding was the cause of death of a second patient. No side effects were noted. A repeat liver biopsy, a year later (4 patients) revealed inactive cirrhosis in all. Chloroquine administration is a safe treatment for patients with
CAH
B. Further studies are justified.
...
PMID:Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. 375 92
We conducted a clinical trial to study the effects of a 10-week course of prednisone therapy and its withdrawal on serum aminotransferase levels and on hepatitis B virus (HBV) markers in patients with hepatitis B surface antigen (HBsAg) positive
chronic active hepatitis
(
CAH
-B). Eighteen patients with
CAH
-B were treated with prednisone, while another 18 patients matched for age, sex, race and sexual preference were followed simultaneously without treatment for the same duration. Nine of 18 prednisone-treated patients became transiently DNA polymerase positive. All nine patients developed a transient rise in serum
alanine aminotransferase
(
ALT
) levels of greater than 300 U/L above baseline values, which was associated with a drop in HBsAg levels from a mean of 186 micrograms/ml prior to therapy to 92 micrograms/ml at 6 months following treatment. Six of these patients developed fatigue, anorexia and dark urine, and four also developed either ascites or hemorrhage from esophageal varices, which was accompanied by hepatic encephalopathy. All six of these patients had histologic evidence of
CAH
with cirrhosis. In comparison, none of the control, untreated patients with
CAH
-B had any change in either HBV markers or serum
ALT
levels. Therefore, even a short course of prednisone in patients with
CAH
-B with cirrhosis is detrimental and its use should be discouraged.
...
PMID:Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. 388 51
An epidemic outbreak of non-A, non-B hepatitis occurred in 1977/78 involving 30 donors at a plasmapheresis center. Of 27 hospitalized patients with peak
ALT
values between 334 and 1736 (mean 831) IU/l, only 16 had subjective symptoms like fatigue and lack of appetite, 11 had nausea, 11 were jaundiced and one developed transient arthritis. Patients with jaundice became chronically ill significantly less frequently than those without jaundice. Nineteen of 26 patients followed up had elevated
ALT
values after 12 months (73%) and 11 after 46 months (42%). Needle liver biopsies performed in 18 of the 19 patients with elevated
ALT
after 12 months revealed chronic persistent hepatitis in 14 and
chronic active hepatitis
in three. Follow-up biopsies always showed improvement (nine patients) or complete recovery (eight patients).
...
PMID:Epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis center. II: Clinical observations and a four-year follow-up of patients. 392 97
We have prospectively studied the clinical data, prognostic factors and chronic liver sequelae in 68 patients who developed posttransfusion non-A, non-B hepatitis. The mean incubation period was 5.9 weeks with a range from 2.1 to 12 weeks; 63.5% of the patients were asymptomatic and 60.6% anicteric. The chronicity rate (elevated
ALT
values for a period of more than 6 months) was 67.6%. The chronicity rate of symptomatic hepatitis (95.5%) was significantly higher than that of asymptomatic hepatitis (54.5%) (P less than 0.01). Monophasic hepatitis, characterized by a rapid elevation in serum
ALT
followed by a rapid decline with no further fluctuations, had a chronicity rate (42.5%) significantly lower than polyphasic hepatitis (86.6%) (P less than 0.05) and plateau type hepatitis (94.4%) (P less than 0.01). Results of 35 liver biopsies carried out among 46 patients with elevated
ALT
after 6 months were as follows:
chronic active hepatitis
, 15 cases; prolonged acute hepatitis, 12 cases; chronic persistent hepatitis, 6 cases; posthepatitis liver changes, 1 case; and secondary hemosiderosis, 1 case.
...
PMID:Posttransfusion non-A, non-B hepatitis. A prospective study. 392 88
Seven children with
chronic active hepatitis
(
CAH
) and one child with persistently abnormal results of liver function test due to hepatitis B virus (HBV) infection were treated with human leukocyte interferon (Hu-alpha-IFN). Five of them were positive for eAg and two of the three who were measured for DNA polymerase (DNAP) activity in sera showed moderate elevations of its levels. Hu-alpha-IFN was injected intramuscularly daily or once weekly at doses of 0.05-1 X 10(6) IU. The total dose per patient varied from 10.5-54 X 10(6) IU. After administration of Hu-alpha-IFN, rapid loss of eAg was observed in two of the five eAg patients, and DNAP activity reverted to normal ranges in the two patients with moderate elevations of its levels. One of the patients who lost eAg has retained normal serum glutamic-oxaloacetic transaminase and
glutamic-pyruvic transaminase
levels for more than 2 years after therapy with Hu-alpha-IFN. Serial hepatic biopsies were performed in only one patient. In the second biopsy, 3 months after therapy with Hu-alpha-IFN, infiltration of inflammatory cells in the portal region was improved compared with earlier findings. Immediate and/or prolonged adverse side effects were not observed during or after administration of Hu-alpha-IFN. For the present, we propose these six conditions for use of Hu-alpha-IFN in children with HBV infection. Children should: (a) be more than 1 year old; (b) have abnormal liver function for more than 6 months; (c) have a liver biopsy demonstrating
CAH
; (d) have moderate elevation of DNAP activity; (e) be eAg positive; and (f) be unresponsive to other treatments.
...
PMID:Therapeutic effects of human leukocyte interferon on chronic active hepatitis B in children. 398 64
To investigate mechanisms of hepatocyte injury, lymphocytes from 41 children with chronic liver disease were incubated with autologous liver cells in a microcytotoxicity assay. Cytotoxicity was significantly increased in 18 of 25 patients with chronic hepatitis B virus (HBV) infection, in five of nine with "autoimmune"
chronic active hepatitis
(
CAH
), and in only one of seven with histologically inactive liver disorders. There was a good correlation between cytotoxicity and biochemical and histologic markers of disease activity in children with autoimmune
CAH
, whereas in HBsAg-positive disease a positive correlation was found only with serum
alanine aminotransferase
(SGPT). Children with autoimmune
CAH
receiving steroid treatment had normal cytotoxicity, whereas increased values were found in two of three HBsAg-positive patients receiving prednisolone. Fractionation studies revealed that non-T cells were cytotoxic in both autoimmune and HBcAg-positive chronic liver disease. T cell cytotoxicity was exclusively found in children with chronic HBV infection, particularly with HBc antigenemia. Blocking experiments showed that T-lymphocytes from HBsAg-positive children reacted with HBV core antigen on the hepatocyte surface. Non-T cells were directed against hepatocyte membrane antigens in both HBsAg-positive and HbsAg-negative children. These results suggest that different immune mechanisms of liver damage are involved in autoimmune and HBsAg-positive chronic liver disease.
...
PMID:Different mechanisms responsible for in vitro cell-mediated cytotoxicity to autologous hepatocytes in children with autoimmune and HBsAg-positive chronic liver disease. 399 45
<< Previous
1
2
3
4
5
6
7
8
9
10